Insights
Search Results
Client Highlights
9.03.26
Wilson Sonsini Advises Scan.com on $220 Million Combined Equity and Debt Financing
On August 31, 2026, Scan.com, a digital medical imaging and radiology booking platform that connects patients, doctors, and diagnostic imaging centers in the U.S. and the UK, announced it has closed $220 million in combined equity and debt financing. The $90 million equity round was led by Noteus Partners, with participation from Aviva, Concord Health Partners, YZR Capital, Oxford Capital, and others. $130 million of debt facilities supporting mergers and acquisitions and working capital were provided by VerisFi Capital and Atempo Growth. Wilson Sonsini Goodrich & Rosati advised Scan.com on the transaction.
Client Highlights
9.01.26
Firm Advises PMV Pharmaceuticals on Oversubscribed $50 Million Public Offering
On August 31, 2026, PMV Pharmaceuticals, a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced the pricing of an underwritten public offering consisting of 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, as well as accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The combined public offering price of each share of common stock and accompanying warrant is $1.21. The gross proceeds from the offering, before deducting underwriting discounts, commissions, offering expenses, and any exercise of the warrants, are expected to be approximately $50.8 million. Wilson Sonsini Goodrich & Rosati advised PMV Pharma on the transaction.
Alerts
8.18.26
CMS Proposes Changes to Incentivize FHIR-enabled Electronic Prior Authorization Use
On July 14, 2026, the Centers for Medicare & Medicaid Services (CMS) announced the CY 2027 Physician Fee Schedule (PFS) proposed rule. The proposed rule includes modifications to further incentivize the use of electronic prior authorization in Medicare Ambulatory Specialty Models (ASMs) and the Merit-based Incentive Payment System (MIPS) by health care providers. This builds on prior CMS regulations related to prior authorization which imposed requirements on certain health plans, but not on health care providers (see 2024 CMS Interoperability and Prior Authorization final rule). These changes are not “PFS” in the technical sense of altering relative value unit (RVU) or conversion-factor payment calculations, but rather are Quality Payment Program (QPP) and Center for Medicare and Medicaid Innovation (CMMI) policy changes that are included in the same omnibus annual rulemaking package. For CMS’s proposed PFS and Hospital Outpatient Prospective Payment System (OPPS) payment changes, see our previous client alert, “Health Reimbursement Signals: CMS Proposes Payment Frameworks for ‘Software as a Medical Service.’”1
Client Highlights
8.18.26
Wilson Sonsini Advises InduPro on $77 Million Series B Financing
On August 12, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced the closing of a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Case Studies
8.14.26
How Wilson Sonsini Helped Soleno Therapeutics Position Itself as an Attractive Acquisition Target
Soleno Therapeutics, a Neurocrine Biosciences company, focuses on the treatment of rare diseases by identifying, developing, and commercializing novel therapeutics. Its lead commercial program addresses Prader-Willi syndrome (PWS), which occurs in approximately one in every 15,000 live births. One of the common symptoms of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense, persistent sensation of hunger.
Client Highlights
8.13.26
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
News Articles
8.12.26
Farah Gerdes Honored as a "Distinguished Leader" for 2026 New England Legal Awards
On August 10, 2026, Wilson Sonsini attorney Farah Gerdes was named among the winners of the “Distinguished Leaders” category for Law.com’s 2026 New England Legal Awards. The awards honor attorneys and firms from Connecticut, Maine, Vermont, New Hampshire, Massachusetts, and Rhode Island.
Client Highlights
8.11.26
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Client Highlights
8.11.26
Firm Advises Expedition Therapeutics on Patent Matters Related to $115 Million Series B
On August 5, 2026, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing led by General Atlantic, a leading global investor, with participation from RA Capital and Vivo Capital and existing investors Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma (a platform controlled by KKR), Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners, and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati is patent counsel to Expedition and advises the company on all patent matters, including those related to this transaction.